The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications

• Published in: Value in health Vol. 13; no. 6; pp. 685 - 694
• Main Authors: Chapman, Richard H., PhD, Kowal, Stacey L., MSc, Cherry, Spencer B., MBA, Ferrufino, Cheryl P., BA, Roberts, Craig S., PharmD, MPA, Chen, Linda, MPhil, MPH
• Format: Journal Article
• Language: English
• Published: Malden, USA Elsevier Inc 01.09.2010; Blackwell Publishing Inc
• Subjects: Adherence; adherence intervention; antihypertensive; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - economics; cardiovascular disease; Cost effectiveness; Cost-Benefit Analysis; Health costs; Humans; Hyperlipidemias - drug therapy; Hyperlipidemias - economics; Hypertension - drug therapy; Hypertension - economics; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - economics; improving adherence; Internal Medicine; Interventions; lipid-lowering; literature review; Medication Adherence; Models, Economic; Quality adjusted life years; Reminders; improving adherence; cost-effectiveness; cardiovascular disease; lipid-lowering; adherence intervention; literature review; antihypertensive
• ISSN: 1098-3015; 1524-4733
• DOI: 10.1111/j.1524-4733.2010.00774.x

Abstract Objective We sought to compare the cost-effectiveness of different interventions that have been shown to improve adherence with antihypertensive and lipid-lowering therapy, by combining a burden of nonadherence model framework with literature-based data on adherence-improving interventions. Methods MEDLINE was reviewed for studies that evaluated ≥1 adherence intervention compared with a control, used an adherence measure other than self-report, and followed patients for ≥6 months. Effectiveness was assessed as Relative Improvement, ratio of adherence with an intervention versus control. Costs, standardized to 12 months and adjusted to 2007 US$, and effectiveness estimates for each intervention were entered into a previously published model designed to measure the burden of nonadherence with antihypertensive and lipid-lowering medications, in a hypertensive population. Outputs included direct medical costs and incremental costs per quality-adjusted life-year (QALY) gained. Results After screening, 23 eligible adherence-improving interventions were identified from 18 studies. Relative Improvement ranged from 1.13 to 3.60. After eliminating more costly/less effective interventions, two remained. Self-monitoring, reminders, and educational materials incurred total health-care costs of $17,520, and compared with no adherence intervention, had an incremental cost-effectiveness ratio (ICER) of $4984 per QALY gained. Pharmacist/nurse management incurred total health-care costs of $17,896, and versus self-monitoring, reminders, and education had an ICER of $6358 per QALY gained. Conclusions Of published interventions shown to improve adherence, reminders and educational materials, and a pharmacist/nurse management program, appear to be cost-effective and should be considered before other interventions. Understanding relative cost-effectiveness of adherence interventions may guide design and implementation of efficient adherence-improving programs